Therapy of Castleman’s disease with siltuximab – case report and review of literature
Authors:
Z. Adam 1; D. Zeman 2; A. Chodacki 3; L. Pour 1; T. Horváth 4; P. Benda 4; Z. Adamová 5,6; M. Krejčí 1; M. Tomíška 1; I. Boichuk 1; Z. Král 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Oddělení klinické biochemie a katedra laboratorních metod, Ústav laboratorní medicíny LF MU a FN Brno
2; PET centrum – nukleární medicína, Masarykova nemocnice, Ústí nad Labem
3; Chirurgická klinika LF MU a FN Brno
4; Chirurgické oddělení, Nemocnice ve Frýdku-Místku
5; Chirurgické oddělení, Vsetínská nemocnice
6
Published in:
Klin Onkol 2023; 37(4): 320-329
Category:
Case Reports
Overview
Background: Idiopathic multicentric Castleman disease (iMCD) is characterized by constitutional symptoms, enlarged lymph nodes and laboratory test abnormalities, which are primarily related to the overproduction of interleukin-6 (IL-6). This form (iMCD) was treated earlier with cytostatics used for lymphoma, later with biologic therapy as rituximab, immunodulatory drugs and proteasome inhibitors, and in the last years with an anti-IL-6 antibody, siltuximab. Siltuximab is a human-mouse chimeric immunoglobulin G1k monoclonal antibody against human IL-6 approved in the European Union for the treatment of iMCD. In view of the limited treatment options for iMCD, this case report aimed to evaluate the efficacy and safety of siltuximab in the management of this condition.
Case: We describe a young woman with iMCD diagnosed at the age of 25 years. For first line treatment, rituximab and dexamethasone were used without any cytostatic because the patient wished to give birth to a healthy child in the future. However, the response after this first line therapy was short. In addition, after 3 years from the start of rituximab + dexamethasone therapy, it was necessary to administer treatment for the relapse of iMCD. We decided for siltuximab in this young woman, still aged < 30 years, and started administration of siltuximab in 3-week intervals.
Results: After administration of first two infusions of siltuximab, all inflammatory markers returned to normal value. Moreover, serum hemoglobin and albumin levels as well as C-reactive protein normalized after the first two administrations of siltuximab. The clinical response continue, siltuximab is still administered in 3-week intervals. PET/CT with fluorodeoxyglucose confirmed a very good anatomic and metabolic response to the treatment. Siltuximab demonstrated a favorable safety profile, and the prolonged treatment was well tolerated.
Conclusion: This result is encouraging and demonstrates the potential of siltuximab as treatment of CD. As earlier published, this case confirms that significantly elevated inflammatory markers in a patient with CD predict a good response to siltuximab.
Keywords:
siltuximab – interleukin-6 – idiopathic multicentric Castleman‘s disease
Sources
1. Fajgenbaum DC, Uldrick TS, Bagg A et al. International, evidence-based consensus diagnostic criteria for HHV--8-negative/idiopathic multicentric Castleman disease. Blood 2017; 129 (12): 1646–1657. doi: 10.1182/blood-2016-10-746933.
2. van Rhee F, Voorhees P, Dispenzieri A et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018; 132 (20): 2115–2124. doi: 10.1182/blood-2018-07-862334.
3. van Rhee F, Oksenhendler E, Srkalovic G et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 2020; 4 (23): 6039–6050. doi: 10.1182/bloodadvances.2020003334.
4. Fajgenbaum DC, vanRhee F, Nabel ChS. HHV-8 negative idiopathic multicentric Castleman disease: novel insight into biology pathogenesis and therapy. Blood 2014; 123 (19): 2924–2933. doi: 10.1182/blood-2013-12-545087.
5. Adam Z, Řehák Z, Adamová Z et al. Unicentric Castlemans disease. Symptoms, diagnostics and therapy. Vnitr Lek 2021; 67 (8): 465–473.
6. Adam Z, Řehák Z, Adamová Z et al. Multicentric Castlemans disease. Symptoms, diagnostics and therapy. Vnitr Lek 2022; 68 (1): 41–53.
7. Adam Z, Pour L, Zeman D et al. Vzácné choroby provázené hypergamaglobulinémií a zánětlivými projevy. Praha: Grada Publishing 2022.
8. Adam Z, Szturz P, Křen L et al. PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview. Vnitr Lek 2013; 59 (4): 301–312.
9. Adam Z, Pour, L, Krejčí M et al. The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis. Vnitr Lek 2012; 58 (11): 856–866.
10. Koukalová R, Selingerová I, Řehák Z et al. FDG-PET/ CT for initial staging and response assessment in Castleman disease – retrospective single-center study of 29 cases. Klin Onkol 2021; 34 (2): 120–127. doi: 10.48095/ccko 2021120.
11. Robey RC, Mletzko S, Colley C et al. The use of monoclonal antibodies to treat Castleman’s disease. Immunotherapy 2014; 6 (2): 211–219. doi: 10.2217/imt.13.167.
12. Kurzrock R, Voorhees PM, Casper C et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19 (13): 3659–3670. doi: 10.1158/1078-0432.CCR-12-3349.
13. Van Rhee F, Wong RS, Munshi N et al. Siltuximab for multicentric Castleman’s disease. A randomized double blind placebo controlled trial. Lancet Oncol 2014; 15 (9): 966–974. doi: 10.1016/S1470-2045 (14) 70319-5.
14. Van Rhee F, Casper C, Voorhees PM et al. A phase 2, open-label multicenter study of long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 2015; 6 (30): 30408–30419. doi: 10.18632/oncotarget.4655.
15. van Rhee F, Rossi JF, Simpson D et al. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. Br J Haematol 2021; 192 (1): e28–e31. doi: 10.1111/bjh.17177.
16. Tonialini L, Bonfichi M, Ferrero S et al. Siltuximab in relapsed/refractory multicentric Castleman disease: experience of the Italian NPP program. Hematol Oncol 2018; 36 (4): 689–692. doi: 10.1002/hon.2532.
17. Ostrowska B, Szymczyk A, Olszewska-Szopa M et al. Efficacy of siltuximab in the treatment of idiopathic multicentric Castleman disease, the first Polish, real-world experience with long-term observation. Leuk Lymphoma 2021; 62 (12): 3031–3034. doi: 10.1080/10428194.2021.1941926.
18. Ebisawa K, Shimura A, Honda A et al. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman‘s disease. Leuk Lymphoma 2021; 62 (3): 614–619. doi: 10.1080/10428194.2020.1834094.
19. Morra DE, Pierson SK, Shilling D et al. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol 2019; 184 (2): 232–241. doi: 10.1111/bjh.15588.
20. Pierson SK, Shenoy S, Oromendia AB et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv 2021; 5 (17): 3445–3456. doi: 10.1182/bloodadvances.2020004016.
21. Mukherjee S, Martin R, Sande B et al. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy. Blood Adv 2022; 6 (2): 359–367. doi: 10.1182/bloodadvances.2021004441.
22. Sun Y, Wang D, Salvadore G et al. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman‘s disease. Brain Behav Immun 2017; 66: 156–164. doi: 10.1016/j.bbi.2017.06.014.
23. Chrysochoou S, Kreft A, Schneider E. Siltuximab-related favorable clinical outcome for a patient suffering from idiopathic multicentric Castleman disease. Case Rep Hematol 2022; 2022: 1840589. doi: 10.1155/2022/1840589.
24. Mukherjee S, Martin R, Sande B et al. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv 2022; 6 (2): 359–367. doi: 10.1182/bloodadvances.2021004441.
25. Fajgenbaum DC, Wu D, Goodman A et al. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol 2020; 95 (12): 1553–1561. doi: 10.1002/ajh.25992.
26. Williams C, Phillips A, Aggarwal V et al. TAFRO syndrome and elusive diagnosis of idiopathic multicentric Castleman disease treated with empiric anti-interleukin-6 therapy. Case Rep Oncol 2021; 14 (3): 1359–1365. doi: 10.1159/000518079.
27. Sandecká V. Siltuximab a jeho léčebné využití u mnohočetného myelomu. Remedia 2021; 31 (5): 480–485.
28. Meira F, Albiach L, Carbonell C et al. Experience with the use of siltuximab in patients with SARS-CoV-2 infection. Rev Esp Quimioter 2021; 34 (4): 337–341. doi: 10.37201/req/045.2021.
29. Gritti G, Raimondi F, Bottazzi B et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia 2021; 35 (9): 2710–2714. doi: 10.1038/s41375-021-013 29-8.
30. Lee H, King G, Garg K et al. Successful treatment of disseminated Rosai-Dorfman disease with siltuximab. Haematologica 2018; 103 (7): e325–e328. doi: 10.3324/haematol.2018.188441.
31. Karkhur S, Hasanreisoglu M, Vigil E et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect 2019; 9 (1): 17. doi: 10.1186/s12348-019-0182-y.
32. Lee YM, Choi YS, Kim JM. POEMS syndrome: presented as idiopathic multicentric Castleman disease of plasma cell variant for eight years and dramatic treatment with siltuximab followed by autologous peripheral blood stem cell transplantation. Diagnostics (Basel) 2022; 12 (4): 998. doi: 10.3390/diagnostics12040998.
33. van Rhee F, Rosenthal A, Kanhai K et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv 2022; 6 (16): 4773–4781. doi: 10.1182/bloodadvances.2022007112.
34. Galeotti C, Tran TA, Franchi-Abella S et al. IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: case report. J Pediatr Hematol Oncol 2008; 30 (12): 920–924. doi: 10.1097/MPH.0b013e31818ab31f.
35. El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman‘s disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 2010; 9 (6): 1485–1488. doi: 10.1158/1535-7163.MCT-10-0156.
36. Jouvray M, Terriou L, Meignin V et al. Pseudo-adult Still’s disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: an atypical presentation of multicentric Castleman’s disease. Discussion of TAFRO syndrome. Rev Med Interne 2016; 37 (1): 53–57. doi: 10.1016/j.revmed.2015.04.006.
37. Rehman MEU, Chattaraj A, Neupane K et al. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: a systematic review. Eur J Haematol 2022; 109 (4): 309–320. doi: 10.1111/ejh.13823.
38. Bayram E, Pehlivan UA, Fajgenbaum DC et al. Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy. Am J Hematol 2023; 98 (2): 361–364. doi: 10.1002/ajh.26783.
39. Shi Y, Li J, Zhang L. Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report. Ann Hematol 2022; 101 (11): 2529–2531. doi: 10.1007/s00277-022-04926-4.
40. Sevindik OG, Mutlu YG, Aydin BB et al. First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of Castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS). Hemasphere 2022; 6 (7): e728. doi: 10.1097/HS9.0000000000000728.
41. Penka I, Kala Z, Zetelová A et al. Castleman’s disease – surgical treatment, case reports. Rozhl Chir 2016; 95 (12): 457–461.
42. Hoffmann C, Hentrich M, Tiemann M et al. Recent advances in Castleman disease. Oncol Res Treat 2022; 45 (11): 693–704. doi: 10.1159/000526640.
43. Sumiyoshi R, Koga T, Kawakami A. Candidate biomarkers for idiopathic multicentric Castleman disease. J Clin Exp Hematop 2022; 62 (2): 85–90. doi: 10.3960/jslrt.22010.
44. Brandstadter JD, Fajgenbaum DC. How we manage idiopathic multicentric Castleman disease. Clin Adv Hematol Oncol 2022; 20 (9): 564–571.
45. Sasaki T, Akiyama M, Kaneko Y et al. Immunoglobulin G4-related disease and idiopathic multicentric Castleman’s disease: confusable immune-mediated disorders. Rheumatology (Oxford) 2022; 61 (2): 490–501. doi: 10.1093/rheumatology/keab634.
46. Cheng CC, Chen YC, Hsu YH et al. Idiopathic multicentric Castleman disease with strikingly elevated IgG4 concentration in the serum and abundant IgG4-positive cells in the tissue: a case report. Diagnostics (Basel) 2022; 12 (9): 2261. doi: 10.3390/diagnostics12092261.
47. Barry KK, Plumptre I, Bazewicz CG et al. Paraneoplastic pemphigus associated with Castleman disease: a multicenter case series. Pediatr Dermatol 2023; 40 (1): 90–95. doi: 10.1111/pde.15138.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2023 Issue 4
Most read in this issue
- Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
- Circulating free DNA and its potential in the diagnostics and therapy of malignant lymphoma
- Therapy of Castleman’s disease with siltuximab – case report and review of literature
- Pět P tuzemské onkologie – pochvala, podpora, polemika, pochybnosti, poklesky